Skip to content
StockMarketAgent
Direct answer
PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $143, high $206, with mid-point at $174.
Stock analysis

PEP PepsiCo Inc. fair value $174–$206

PEP
By StockMarketAgent.AI team· supervised by
Analizado: 2026-05-08Próxima actualización: 2026-08-08Methodology v2.4Archetype: Mature dividendNASDAQ · Consumer Staples
View archive
Precio
$154.62
▲ +19.79 (+12.80%)
Valor razonable
$174
$174–$206
Calificación
Comprar
confidence 88/100
Potencial alcista
+12.8%
upside to fair value
Margen de seguridad
$148.25
buy below · 15%
Capitalización bursátil
$211.4B
P/E fwd 16.9
Respaldo en inglésES
Mostrando la fuente en inglés mientras traducimos
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.

§1 Resumen ejecutivo

  • Composite fair value $174 with high case $206.
  • Implied upside of 12.8% to fair value.
  • Moat 9/10 · confidence 88/100 · Mature dividend.
  • Trades at a measured discount to fair value with adequate margin of safety.
Fair value
$174
Margin of safety
+11.3%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$154.62Price
FV $174.41
High $206.45

PEP trades against a final fair-value range of $142.66-$206.45, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Deep global distribution networks covering
    Deep global distribution networks covering developed and emerging markets.
  • Immense brand equity and pricing
    Immense brand equity and pricing power across both beverage and snack portfolios.
  • Bull thesis
    Valuation synthesis intentionally anchors heavily on Forward Earnings to mitigate terminal value dominance.

§2 Caso bajista

A sustained macroeconomic downturn coupled with accelerated adoption of GLP-1 weight-loss drugs leads to structural volume declines and an inability to offset cost inflation through pricing, heavily compressing operating margins and driving free cash flow below historical norms.

Cómo puede fallar esta tesis

GLP-1 Widespread Adoption

· Medium

Mass adoption of appetite-suppressing GLP-1 drugs permanently reduces per-capita consumption of high-calorie snacks and sugary beverages, breaking historical volume baselines.

FV impact
-25%
Trigger
3-5 years

Total Loss of Pricing Power

· Low

Consumer fatigue over successive price hikes forces aggressive discounting and promotional activity to defend market share against private label brands, destroying gross margins.

FV impact
-20%
Trigger
1-2 years

Supply Chain and Input Cost Shock

· Medium

Extreme agricultural commodity inflation and localized supply chain disruptions structurally elevate the cost base beyond what can be passed to consumers, permanently compressing operating margins.

FV impact
-15%
Trigger
1-3 years
Señales de alerta temprana a vigilar
MétricaActualUmbral de activación
Consecutive quarters of negative organic volume growth.MonitorDeterioration versus the report thesis
Gross margin compression exceeding 150 basis points.MonitorDeterioration versus the report thesis
Substantial shift in market share to private label brands.MonitorDeterioration versus the report thesis
Significant downward revisions in forward consensus earnings.MonitorDeterioration versus the report thesis
Unplanned increases in promotional spend to clear inventory.MonitorDeterioration versus the report thesis

§3 Historial financiero

Cuenta de resultados — últimos seis períodos
ConceptoT−0T−1T−2T−3CAGR
Período2022-12-312023-12-312024-12-312025-12-31Trend
Ingresos$86.39B$91.47B$91.85B$93.93B+2.8%
Beneficio bruto$45.82B$49.59B$50.11B$50.86B+3.5%
Beneficio operativo$11.36B$12.91B$12.92B$13.49B+5.9%
Beneficio neto$8.91B$9.07B$9.58B$8.24B-2.6%
BPA (diluido)$6.42$6.56$6.95$6.00-2.2%
EBITDA$14.92B$15.75B$16.68B$15.54B+1.4%
I+D
SG&A$34.46B$36.68B$37.19B$37.37B+2.7%

Puntuaciones de calidad

Piotroski F-score
5 / 9
Compuesto de calidad 0–9
Altman Z-score
3.59
Riesgo de quiebra (>3 seguro)
Beneish M-score
-2.56
Riesgo de manipulación de beneficios
OCF / Beneficio neto
1.47×
>1 indica alta calidad de los beneficios
Umbral de calidad contable
Pass
Umbral ajustado por sector
ROIC
12.8%
Rentabilidad del capital invertido
Sección 3

Numbers analysis

Asignación de capital

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Suscriptores individuales — desde §411 secciones más

Leer el análisis completo — 11 secciones más.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Informe completo para cada ticker cubierto
24 meses de archivo de calificaciones
Briefings de lista de seguimiento + alertas de cambio de calificación
Exportación PDF + DOCX en cualquier idioma
Comenzar prueba gratuita
Cancela cuando quieras.
FAQ

PEP — frequently asked questions

  1. Based on our latest analysis, PEP looks modestly undervalued. The current price is $155 versus a composite fair-value midpoint of $174 (range $143–$206), which implies roughly 12.8% upside to the midpoint.
Related coverage

Names readers of PEP also follow

Same archetype: mature-dividend
Same sector: Consumer Staples